(Total Views: 230)
Posted On: 05/02/2017 8:40:44 AM
Post# of 1193
CBIS News - Cannabis Science Senior Executives Chair Special Sessions and Deliver a Keynote Speech at the Global Health Catalyst Summit at Harvard Medical School
IRVINE, CA -- (Marketwired) -- 05/02/17 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce its President, CEO, and Co-Founder, Mr. Raymond C. Dabney, and his team have successfully participated in the Global Health Catalyst (GHC) Summit hosted by the Dana-Farber Cancer Institute/Harvard Cancer Center (DF/HCC). The DF/HCC is a collaborative organization that integrates five Boston-area academic medical institutions and two Harvard schools -- Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, Harvard Medical School, and the Harvard T.H. Chan School of Public Health at Harvard Medical School. The summit is designed to catalyze high impact international collaborations in health care, education and research.
Mr. Dabney was the keynote speaker for the Cannabis Science versus Cancer and Other Malignancies Session, which was one of the highlights of the three-day Summit. CBIS' Chief Medical Officer, Dr. Allen Herman, Chaired the Cannabis Science Session, and also delivered a presentation on the epidemiology of cancer and the utilization of opioids in Africa and across the world during the Palliative Care and Mental Health Session. The Company is cleaning up the recorded video feed of the CBIS Session for enhanced clarity; distribution will be made available for viewing over the internet available shortly.
"We were pleased to share our vision with an impressive array of senior health care professionals from the USA and across the world including Africa and the broad African Diaspora. We were particularly pleased with our successful meetings with the Ministers of Health of Namibia, Rwanda, and Kisumu County in Kenya. These African health leaders will help CBIS to define our strategy on the African continent. We are launching an aggressive research program with Dana Farber, and we expect a number of major developments in 2017," said Dr. Herman.
Mr. Dabney stated, "Our participation in the GHC Summit and this speaking opportunity gave us an opportunity to discuss cutting-edge cannabinoid research with some of the greatest minds in modern medicine globally, as well as to network and explore potential partnerships." In addition, CBIS' participation in this Summit provided the company with an opportunity to update stakeholders regarding the progress of the implementation of CBIS' research agreement with Dana-Farber. "I believe the CBIS/Dana Farber relationship is off to a very good start, and I am excited about the potential of our collaboration. I am even more excited about the groundbreaking initiative with Dana-Farber that we plan to jointly announce in the next few days. This upcoming announcement will change the narrative of how we approach the research, development, and clinical trials of cannabinoid-based medicines globally."
IRVINE, CA -- (Marketwired) -- 05/02/17 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce its President, CEO, and Co-Founder, Mr. Raymond C. Dabney, and his team have successfully participated in the Global Health Catalyst (GHC) Summit hosted by the Dana-Farber Cancer Institute/Harvard Cancer Center (DF/HCC). The DF/HCC is a collaborative organization that integrates five Boston-area academic medical institutions and two Harvard schools -- Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, Harvard Medical School, and the Harvard T.H. Chan School of Public Health at Harvard Medical School. The summit is designed to catalyze high impact international collaborations in health care, education and research.
Mr. Dabney was the keynote speaker for the Cannabis Science versus Cancer and Other Malignancies Session, which was one of the highlights of the three-day Summit. CBIS' Chief Medical Officer, Dr. Allen Herman, Chaired the Cannabis Science Session, and also delivered a presentation on the epidemiology of cancer and the utilization of opioids in Africa and across the world during the Palliative Care and Mental Health Session. The Company is cleaning up the recorded video feed of the CBIS Session for enhanced clarity; distribution will be made available for viewing over the internet available shortly.
"We were pleased to share our vision with an impressive array of senior health care professionals from the USA and across the world including Africa and the broad African Diaspora. We were particularly pleased with our successful meetings with the Ministers of Health of Namibia, Rwanda, and Kisumu County in Kenya. These African health leaders will help CBIS to define our strategy on the African continent. We are launching an aggressive research program with Dana Farber, and we expect a number of major developments in 2017," said Dr. Herman.
Mr. Dabney stated, "Our participation in the GHC Summit and this speaking opportunity gave us an opportunity to discuss cutting-edge cannabinoid research with some of the greatest minds in modern medicine globally, as well as to network and explore potential partnerships." In addition, CBIS' participation in this Summit provided the company with an opportunity to update stakeholders regarding the progress of the implementation of CBIS' research agreement with Dana-Farber. "I believe the CBIS/Dana Farber relationship is off to a very good start, and I am excited about the potential of our collaboration. I am even more excited about the groundbreaking initiative with Dana-Farber that we plan to jointly announce in the next few days. This upcoming announcement will change the narrative of how we approach the research, development, and clinical trials of cannabinoid-based medicines globally."
(0)
(0)
